Introduction
The increased understanding of the molecular pathogenesis of cancer has profoundly changed the view of the disease. Its development is now considered as resulting from multiple genetic alterations. 1 However, the introduction of a recombinant construct encoding a single tumor suppressor protein can counterbalance the effects of multiple mutations and eventually reverse the phenotype of certain cancer cells. 2 The first tumor suppressor that has been transferred to a variety of tumor tissues was wild-type (wt) p53. [2] [3] [4] This tumor suppressor plays a central role in both regulation of cell proliferation and apoptosis; its normal function is lost in the majority of tumors including non small-cell lung cancer (NSCLC). 5 Thus, the hope was that reintroduction of this gene into p53-deficient tumors or overexpression in p53-positive tumors would inhibit tumor growth. (see Ref. 6 for review). We and others previously reported that restoring the wt p53 gene by viral or nonviral vectors inhibited the growth of NSCLC cell lines in vitro and in vivo. [7] [8] [9] [10] There is evidence that the apoptotic activity of wt p53 is of central importance for its tumor suppressor activity. 11 However, the relative contribution of cell cycle arrest versus apoptosis in p53-mediated tumor regression has not been extensively documented. Furthermore, wt p53 antitumoral activity might be dependent for its activity on other suppressor factors such as inhibitors of angiogenesis. The low transfection efficiency of most available vectors makes it difficult to analyze precisely the mechanisms of the antitumoral effect of wt p53, such as the relative contribution of cell cycle arrest and apoptosis. Therefore, we developed an inducible tumor cell line in which wild-type p53 gene expression is controlled by a tetracycline-dependent promoter. 13, 14 Using this model, we recently showed that induction of wt-p53 increases the expression of the pro-apoptotic BAX protein in its native, inactive conformation without triggering apoptosis.
14 Thus, we used this model to analyze whether or not the antitumoral activity of wt p53 is dependent on its pro-apoptotic function. In this report, we show that wt p53-mediated cell cycle arrest is sufficient to induce tumor regression in vivo.
Results

Wild-type p53 induces cell cycle arrest in vitro
The p53-null H358 cell line was transfected with the wt p53 gene placed under the positive control of a tetracycline-dependent promoter. From the seven H358/TetOn/p53 clones obtained after G418 selection, three were used for subsequent studies. Results obtained in clone 7 are representative of the two other clones and are shown in the Figures and Table. The induction of p53 starts 4 h after addition of dox, reaches its maximum at 24 h and remains elevated throughout the 13-day time period studied ( Figure 1a) . Cells stop proliferating after p53 induction (Figure 1b) . The p53-expressing cells were analyzed by flow cytometry for DNA content after propidium iodide staining. p53-positive cells undergo a G 0 /G 1 cell cycle phase arrest 24 h after dox treatment ( Figure Figure 1 ( 1c), which is preceded by an up-regulation of the cyclindependent kinase inhibitor (CDKi) p21 (Figure 1d) . After 48 h, p53 induces a significant accumulation of cells in G 2 /M phase (from 19.9% in p53-null cells to 30.3% in p53-expressing cells), while the proportion of cells in the S phase decreases more than two-fold. Simultaneously, a down-regulation of cyclin B 1 is observed while levels of 14-3-3-σ or mdm2 remain constant (Figure 1d ). The H358/TetOn cell line transfected with an empty vector does not show changes in cell cycle distribution nor in protein expression that exclude a nonspecific effect of dox.
Wild-type p53 does not induce apoptosis, but senescence in vitro
The ability of p53 to induce apoptosis was evaluated in vitro by morphological analysis of cells after Hoechst staining and analysis of pro-caspase-3 proteolytic acti- Figure 2B ). Accordingly, dox-treated cells do not express the p12-active fragment of caspase-3 ( Figure 2B ), nor do they accumulate in the sub-G1 peak characteristic of apoptosis ( Figure 1c ). As we previously described, 14 the absence of apoptosis is observed even though the pro-apoptotic BAX protein expression is induced (Figure 1d ). Induction of p53 does not influence BCLxL expression and the level of BCL2 protein is too low to be detected by Western blot analysis.
However, p53-expressing cells present an enlarged size as compared with p53-nonexpressing cells. The morphologically altered phenotype and the growth inhibition are both hallmarks of senescence. This is confirmed by the detection of senescence associated (SA)-␤-galactosidase activity in p53-expressing cells (Figure 2c ). In contrast, SA-␤-galactosidase staining is not detected in control noninduced cells.
Wt p53 does not inhibit human telomerase reverse transcriptase (hTERT)
The capacity of wt p53 to induce senescence through inhibition of hTERT expression was studied by real-time RT-PCR. As shown in Table 1 , the level of expression of hTERT is very low compared with the house-keeping gene PBGD used as an internal control. There is no variation between results obtained in samples cultured with or without dox suggesting that p53 does not affect hTERT in these cells. Figure 3 , transient overexpression of wt p53 still induces apoptosis in H358/TetOn/p53 cells at a similar level to that observed in the parental cell line.
Antitumoral activity of wt p53 in vivo is associated with cell cycle arrest, but not apoptosis
To determine the effect of p53 expression in vivo, 20 × 10 6 H358/TetOn/p53 cells were injected subcutaneously in nude mice and allowed to grow. Once tumor diameters reached 4-5 mm 3 , mice were divided into two groups; one was treated with dox, whereas the other was left untreated. Of note, growth kinetics of H358 parental cells, H358/TetOn and H358/TetOn/p53 in nude mice were very similar (data not shown). In treated mice, tumors completely regressed in all animals within 30 days after the beginning of dox treatment ( Figure 4 ). These animals were followed for another 3 months after cessation of dox treatment and remained tumor-free. In contrast, tumors grew in all untreated mice.
Morphological features and immunostaining profiles 
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Cells are incubated for the indicated time without (Ϫ) or with (+) of doxycycline (1 g/ml). Results obtained on clone 7 and are representative of three independent experiments. PBGD (prophobilinogen deaminase) is used as a house-keeping gene to normalize each sample and results are expressed as the ratio of mRNA copy numbers for hTERT and PBGD in each sample.
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Figure 3 Apoptosis induction in H358/Teton/p53 cells after nonviral transfection of wt p53 gene. Malignant cells were transfected as previously described with empty vector or a plasmid coding for wt p53. Transfection efficiency reached 25 ± 5% in H358 parental cell line or H358/Teton/p53 clones. Apoptosis is quantified 72 h after transfection by morphological changes of Hoechst-stained cells. Staurosporin-treated sample is used as a positive control of apoptosis which ranged between 8 and 10% (data not shown). , H358/teton/p53 clone, untreated control; H358 parental cell line: untreated control; H358/teton/p53 transfected with empty vector;
H358/teton/p53 transfected with plasmid coding for wt p53; H358 parental cell line transfected with plasmid coding for wt p53. 
Discussion
We recently showed that stable expression of wt p53 in a p53 null tumor NSCLC cell line induces in vitro the expression of the pro-apoptotic BAX protein in its native, inactive conformation without triggering apoptosis. 14 We thus used this model to analyze the relative contribution of p53-mediated cell cycle arrest versus apoptosis in tumor regression and we showed first that the stable expression of wt p53 leads to a dramatic and long-lasting regression of pre-established human NSCLC tumors grafted in nude mice; and second that p53-mediated cell cycle arrest is sufficient to induce this antitumoral effect.
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transformation by wt p53 has been well established, 11 its role in tumor regression has not been extensively documented due to the difficulty in quantifying apoptosis in tumor samples and the very low efficiency of gene transfer in vivo. The local application of p53-encoding vectors in cancer cells in vivo, inhibited tumor growth in most of the published models, 4,7,9,10 but signs of apoptosis were inconsistent. We previously showed that transient nonviral transfection of BAX and p53 genes in NSCLC exhibit a similar antitumoral activity in vivo, despite a strong difference in their capacity to induce apoptosis. 9 The p21 CDKi gene transfer has been reported to suppress tumorigenicity in vivo without apoptosis, but with an accumulation of cells in G 0 /G 1 , an altered morphology and terminal cell differentiation. 16 In the present study, restoration of p53 using the inductible expression system induces tumor regression through cell cycle arrest and without apoptosis. Accordingly, the in vitro study reveals that, in these experimental conditions, p53 increases the expression of p21 and inhibits cell proliferation in the G 0 /G 1 and G 2 /M cell cycle phases, but does not activate apoptosis. These results are not related to an irreversible alteration in the capacity of cells to respond with apoptosis during the selection of inductible clones, since overexpression of wt p53 by transient transfection still induces apoptosis in H358/TetON/p53 clones. Furthermore, we showed that in vitro treatment of this clone with caffeine is able to trigger apoptosis through the conformational change of BAX and its translocation to the mitochondria. 14 Determinants that dictate which of the apoptosis or growth arrest pathways is activated following p53-expression remain largely obscure. Several studies provide evidence that the level of p53 expression is critical. [16] [17] [18] [19] Comparison between detached and attached fibroblasts after oxidative stress showed that detached apoptotic cells present a strong increase in the p53 protein level, whereas attached growth arrested cells show a moderate p53 expression. 18 Mukhopadhyay and Roth 19 have shown that the superinduction of p53 by 2-methoxyestradiol induces apoptosis of adenovirally p53-transduced cells and potentiates the antitumoral effect of p53 gene transGene Therapy fer in vivo. In gene therapy experimental protocols, transient gene transfer usually induces a strong expression of p53 in the transfected cells; it might also provide a second signal necessary for the cells to undergo apoptosis, as observed in our model with caffeine. In contrast, the lower level of p53 expression when the gene becomes stably integrated might lead to cellular growth arrest rather than apoptosis.
Our results also show that wt p53 expression is associated in vitro with senescence in a cell line known to express an oncogenic RAS, wt Rb but no p53 nor p16 protein. 20, 21 Thus, in the H358 cell line, expression of p53 might restore the senescence pathway activated by the Ras oncogene. 22, 23 As previously shown, 23 p53-mediated senescence is associated with G 0 /G 1 and G 2 /M cell cycle arrest, p21 induction and down-regulation of cyclin A, cyclin B1 and cdc2. Furthermore, down-regulation of hTERT expression, a key enzyme in the control of the telomerase activity and the senescence process, 24, 25 is not observed in our model, in accordance with observations of a telomere-independent clock in cells expressing oncogenic RAS. 26, 27 Previous publications have shown that irreversible growth arrest and senescence suppressed tumorigenicity in vitro as measured by the loss of colony formation. 27 In our experiments, cell cycle arrest and senescence are observed in vitro, but in vivo cell cycle arrest is the only obvious characteristic of p53 expressing cells. In tumors taken up to 20 days after the beginning of the treatment, p53 expression does not induce major morphological changes. The localization and number of blood vessels are very similar in treated and non-treated tumors, as the expression of thrombospondin I, the best-characterized p53-induced inhibitor of angiogenesis, in treated tumors (data not shown). These data suggest that in our model, p53 does not induce inhibition of angiogenesis, a mechanism known to be part of the p53-mediated tumor regression. 28, 29 Then, the simplest hypothesis to explain our results is the daily death of a few percent of malignant cells as shown by necrosis observed in all samples. Then in the absence of cell proliferation, p53 expressing tumors progressively regress. However, molecular analysis has previously identified changes in gene expression that occurs when cells stop proliferating and become senescent. 30 These molecular changes might contribute to tumor regression in the absence of major morphological changes. Experiments are ongoing to compare the profile of genes expression in p53 expressing and non-expressing tumors.
In conclusion, we have shown that wt p53-mediated cell cycle arrest is sufficient to induce long-lasting tumor regression. This suggests that p53 gene therapy should be efficient even if malignant cell apoptosis is inhibited, as frequently observed in human tumors. These results clearly strengthen the argument for a therapeutic strategy based on wt p53 gene transfer in tumors and open new opportunities for combining the therapy with other approaches.
Materials and methods
Cell line, culture and analysis of growth and apoptosis
The human NSCLC cell line H358 of bronchioloalveolar origin (ATCC CRL5807), has a homozygous deletion of p53. Cells were cultured as adherent monolayers in RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated fetal calf serum, and glutamine (2 mm) at 37°C in a humidified atmosphere of 5% CO 2 . All products were purchased from Gibco, Cergy Pontoise, France.
H358/TetOn/P53 clones were maintained in RPMI 1640 medium, 10% fetal calf serum, glutamine, supplemented with hygromycin (50 g/ml) and geneticin (G418: 100 g/ml) (both from Gibco). To induce p53 expression, doxycycline (dox) (Sigma, Saint Quentin Fallavier, France) was added to the medium to a final concentration of 1 g/ml which is not toxic.
For growth assay, cells were plated at the density of 50 000/cm 2 , harvested at different time intervals, and counted in a Mallasez chamber. Cell viability was evaluated by trypan blue exclusion assay.
The morphological changes of apoptosis were assessed by fluorescence microscopy after staining of cells with Hoechst 33 342 (5 g/ml), and the percentage apoptosis was scored after counting at least 200 cells.
Plasmid construction
To study the biological effect induced by p53, we used a modified tetracycline-regulated inducible expression system (Tet-On system; Clontech, Ozyme, Saint Quentin en Yvelines, France). The cell lines were obtained according to the manufacturer's instructions.
Briefly, H358 cells were transfected with the pTet-On plasmid, which contained the reverse tetracycline repressor (rtTA) expression cassette and the neomycin gene (neo r ), using TFX-50 (Promega, Charbonnières, France) and transferrin (Tfe) (Becton Dickinson, Le Pont de Claix, France), as described previously. 9 Transfectants were selected in the presence of G418 (800 g/ml). Stable H358/Tet-On were screened by transient transfections with pTRE-Luc plasmid. After 24 h of induction with dox, the luciferase assay was performed using the Promega luciferase assay system as recommended. One H358/TetOn clone was selected. This clonal cell line shows a very high induction of luciferase in response to dox and a low background in the absence of dox. pTRE-p53 plasmid was constructed by subcloning wild-type (wt) p53 cDNA downstream of the Tet-regulated promoter into pTRE plasmid. H358/TetOn cell line was cotransfected using liposome-mediated transfection methods (TFX-50 and Tfe) with pTRE-p53 and pTK-Hyg plasmids containing hygromycin gene (hyg r ). Double transfectants were selected in the presence of hygromycin (200 g/ml) and geneticin (100 g/ml).
Individual clones of stable double transfectants, named H358/TetOn/P53, were screened by transfection with RGC lacZ plasmid (gift from Thierry Frebourg, U INSERM, Paris, France) which contains the LacZ gene under a p53-inducible promoter. LacZ expression after wt p53 protein expression was evaluated in situ by color reaction with the ␤-gal substrate 5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside (X-Gal, Gibco). Twentyfour hours after transfection, cells were fixed with a solution of 1% formaldehyde and 0.5% glutaraldehyde in phosphate buffered saline (PBS) for 5 min at room temperature, then exposed to X-Gal (0.4 mg/ml) in PBS in the presence of 4 mm potassium ferricyanide, 4 mm ferrocyanide, 0.002% Nonidet P-40 (NP-40) and 2 mm MgCl 2 for 3 h at room temperature.
Seven H358/TetOn/p53 clones expressing a significant level of p53 protein after dox treatment were obtained and three were selected for experiments. Sequence analysis of the p53 gene showed that a polymorphic form of wt p53 (Arg 72 → pro 72) was inserted into the three clones, this polymorphic form has pro-apoptotic activity.
Transient nonviral transfection of parental H358 cell line and H358/TetOn/p53 clones H358 parental cell line and H358/TetOn/p53 clones were transfected as previously described, 9 using TFX-50 (Promega) and transferrin (Tfe) (Becton Dickinson). The empty pcDNA3 plasmid (Invitrogen, Carlsbad, CA, USA) was used as a control. Plasmid pC53-SN allowed the expression of wt p53 under the control of the cytomegalovirus (CMV) promoter. Using this technique, the transfection efficiency reached 25 ± 5% in both parental cell line and H358/TetOn/p53 clones.
Immunoblotting
Cells were washed twice in PBS and incubated in lysis buffer (Tris-Hcl 50 mm pH 7.4, NaCl 150 mm, EDTA 1 mm, NP-40 0.5%, NaF 1 mm, NaVO 4 1 mm, PMSF 0.1 mm, leupeptin 10 g/ml, aprotinin 10 g/ml and pepstatin) for 30 min on ice. Protein content was assessed by the BioRad D C Protein Assay kit (BioRad Laboratories, Ivry sur Seine, France). Cell lysates (20-40 g of total proteins) were subjected to polyacrylamide gel electrophoresis and transferred to PVDF membranes (Millipore, Saint Quentin Yvelines, France). After blocking nonspecific binding sites with 5% nonfat milk in TPBS (PBS, Tween-20 0.05%) for 30 min at room temperature, the membrane was incubated overnight at 4°C with primary antibody diluted in PBS. The primary used antibodies were antihuman p53 mouse monoclonal Ab (DO7, Dako, Trappes, France), anti-human p21
Waf1/CIP1 mouse monoclonal antibody (Oncogene, Fontenay-Sous-Bois, France), antihuman cyclin B1 mouse monoclonal antibody (Pharmingen, Becton Dickinson), anti-human BAX rabbit polyclonal antibody (Pharmingen, Becton Dickinson), anti-human Bclx rabbit polyclonal antibodies (Transduction Laboratories, Interchim, Montlucon, France), anti-human mdm2 mouse monoclonal antibody (NovoCastra Laboratory, Tebu, Le Parray-en-Yveline, France) and anti 14-3-3 goat polyclonal antibody (Santacruz, Tebu, Le Parray-en-Yveline, France), anti-human caspase-3 rabbit polyclonal antibody (Pharmingen, Becton Dickinson). To ensure equal loading and transfer, membranes were also probed for actin, using anti-actin rabbit polyclonal antibody (Sigma-Aldrich, Saint Quentin Fallavier, France).
The immunoreactive proteins were visualized using horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit antibody and enhanced chemoluminescence (ECL; Amersham Pharmacia Biotech, Orsy, France).
Flow cytometry analysis of cell cycle distribution
At different times after p53 induction, cells were washed in ice-cold PBS, fixed in ethanol 70% for 30 min and incubated for 15 min in the presence of RNAse A (20 g/ml). Cellular DNA was stained with propidium iodide (PI 10 g/ml in PBS; Roche Diagnostic, Meylan, France). Analysis was performed on a Becton Dickinson FACScan flow cytometer. Green fluorescence (FITC, FL-1) was detected at 530 nm and red fluorescence (PI, FL-2) at 575 nm.
RNA extraction and quantitative determination of hTERT mRNA expression
Total RNA was extracted by using the acid-phenol method (RNAgents total RNA isolation system, Promega) following the manufacturer's instructions and quantified by absorption at 260 nm.
Telomerase hTERT components were detected by quantitative, one-step RT-PCR with the Light-cycler instrument using the Telo TAGGG hTERT quantification kit (Roche, Meylan, France). Briefly, telomerase (hTERT) encoding mRNA is reverse transcribed from 200 ng of total RNA and a 198-bp fragment of the generated cDNA is amplified with specific primer. Using Light-cycler technology, reactions were characterized by the point during cycling when amplification of the PCR product is first detected rather than the amount of PCR product accumulated after a fixed number of cycles. This amplification was detected by fluorescence using a specific pair of hybridization probes. The kit also provides prediluted RNA standards for establishing a reference curve and determining precisely the numbers of hTERT mRNA copies in each sample. In a separate one-step RT-PCR, mRNA encoding for prophobilinogen deaminase (PBGD) was processed for use as house-keeping gene to normalize each sample.
The results were expressed as the amount of hTERT transcript divided by the amount of endogenous housekeeping gene PBGD.
Tumor treatment
Experiments were conducted on 25-week-old female Swiss nude mice (Iffa Credo, Marcy l'Etoile, France). Animals were injected subcutaneously with 20 × 10 6 H358/TetOn/p53 cells. Two to 3 weeks later, when tumor diameters ranged from 4 to 5 mm, 10 mice were exposed to dox (2 mg/ml) added to their drinking water for 24 days; other animals were left untreated. All animals were then left untreated until day 60 where possible, and even longer for tumor-free animals. The tumors were measured once a week in two perpendicular diameters. The volume was calculated as follows: a × b 2 × 0.4, where 'a' and 'b' are the largest and smallest diameters, respectively.
Immunohistochemical staining and TUNEL assay
Two mice from the untreated doxycycline-treated groups were killed 1, 5, 8 and 20 days after the beginning of treatment. Tumors were harvested and fixed in 10% formalin or frozen in Tissue-Tek OCT (Sakura Finetek Europe, Zoeterwoude, the Netherlands). Paraffin sections (4 mm) were deparaffinized. Morphological analysis was performed after HES (hemalin, eosin, saffron)-staining or periodic acid-Schiff reaction (PAS), a specific counterstaining for mucous cells. For p53 detection, sections were treated by steam heat for 2 × 5 min in citrate buffer pH 6, then incubated with 2% milk solution for 30 min at room temperature. For Ki67 immunolabeling, sections were steamed for 3 × 7 min before incubation. Monoclonal mouse anti-human p53: DO-7 (1/20: Dako, La Trappes, France) or monoclonal mouse anti-human Ki67: (Mib1: Immunotech, Coulter, Marseille, France) were incubated overnight at 4°C. Sections were incubated with biotin-conjugated donkey anti-mouse Ig (1/500, Jackson Immunoresearch, Interchim, Montlucon, France) for 1 h at room temperature and streptavidin-biotin perGene Therapy oxidase complex for 1 h at room temperature (complex ABC peroxidase, Dako). Sections were washed thoroughly in PBS between immunostaining procedures. The final reaction product was visualized with diaminobenzidine. After immunohistochemical reactions, sections were counterstained with hematoxylin. Negative controls were performed with the same sections only incubated with the secondary antibody. The active fragment of caspase 3 was detected on frozen sections fixed with 3.7% paraformaldehyde for 10 min, and saturated for 30 min with a solution of normal donkey serum at 2%. Polyclonal rabbit antihuman/mouse active caspase-3 (1/5000, R&D System Europe, Abingdon, UK) was incubated overnight at 4°C, followed by a 1-h incubation at room temperature with biotin-conjugated donkey anti-rabbit Ig (1/1250, Jackson) and streptavidin-biotin phosphatase complex for 1 h at room temperature (Dako). Fast red (Sigma) was then used for 5 to 10 min in order to provide the red color. Frozen sections were also used for immunodetection of Bax, Bcl2, CD31. Sections were fixed with acetone 10 min at -20°C, then saturated and incubated with a monoclonal antibody directed against anti-Bax polyclonal antibody (1/200: SantaCruz, Tebu, Le Perrayen-Yveline, France) or anti-Bcl2 monoclonal antibody (1/100: Dako). For CD31 immunolabeling, tumor cells were fixed for 2 min at room temperature with 3.7% PAF, then incubated with an anti-rat CD31 antibody (1/2000: Dako) overnight at 4°C. Sections were then incubated with biotin-conjugated goat anti-rat antibody for 1 h at room temperature and streptavidin-biotin peroxidase complex (Dako) for 1 h at room temperature.
Apoptotic cells were detected by TUNEL reaction. Briefly, apoptosis-related fragmentation was analyzed by Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) using the in situ cell death detection kit (Boehringer Mannheim). Cells were labeled as described previously. 31 Cytochemical detection of senescence-associated ␤-galactosidase staining The SA ␤-galactosidase staining was detected as previously described. 32 Briefly, cells were plated in six-well plates and incubated for 8 days in the presence of doxycycline (1 g/ml). The density of cells was adjusted in order to have the same cell density in treated and untreated wells at the end of the experiment. Cultured cells and frozen sections from 8-day tumors were fixed with 2% formaldehyde/0.2% glutaraldehyde in PBS for 5 min at room temperature and washed in PBS. Senescence-associated ␤-galactosidase was detected by incubating the specimen in stain solution (1 mg/ml 5-bromo-4-chloro-3-indolyl-␤-d-galactosidase (X-gal) in dimethylformamide (20 mg/ml stock), 40 mm citrique acid/sodium phosphate pH = 6, 5 mm potassium ferrocyanide, 5 mm potassium ferricyanide, 150 mm NaCl 2 ) for 2 to 5 h. Specimens were washed in PBS and counterstained with neutral fast red while sections were counterstained with hematoxylin.
(Unité de l'Isère) and FEGEFUC, as well as by grants from the region Rhô ne-Alpes (programme emergence) and from the Health Ministry (CRTG). Laurence Dubrez acknowledges ARC and region Rhô ne-Alpes for research fellowships.
